Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion

Zhang, Lu; Dopfer-Jablonka, Alexandra; Cossmann, Anne; Stankov, Metodi V.; Graichen, Luise; Moldenhauer, Anna-Sophie; Fichter, Christina; Aggarwal, Anupriya; Turville, Stuart G.; Behrens, Georg M.N.; Pöhlmann, Stefan; Hoffmann, Markus

doi:10.1016/j.isci.2024.109904

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint3

Article2

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19

Oliveira,

Monteleone-Cassiano,

Tavares

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19

Oliveira,

Monteleone-Cassiano,

Tavares

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants

Piepenbrink,

Khalil,

Chang

et al. 2024

npj Viruses

View full text Add to dashboard Cite

Humoral Immune Responses in German Dialysis Patients after mRNA Omicron JN.1 Vaccination

Stankov,

Hoffmann,

Happle

et al. 2024

Preprint

View full text Add to dashboard Cite

To assess the effect of the updated mRNA JN.1 omicron vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany) in an immunocompromised and elderly population, we measured humoral immune responses after mRNA omicron JN.1 vaccination in 37 haemodialysis patients before and 21 days after vaccination. We observed a 3-fold change in anti-S IgG, and a 4.7-fold change in anti-S omicron IgG. Memory B cells (MBC) exclusively binding the receptor binding domain (RBD) of JN.1 displayed a median frequency of 0.11% before vaccination and changed significantly 3.9-fold to a median of 0.43%. Cross reactive JN.1 RBD and Wuhan-Hu-1 S-binding MBCs and MBCs only binding to Wuhan-Hu-1 S changed 2.3-fold and 1.8-fold, respectively. Using a vesicular stomatitis virus-based pseudovirus particle (pp) neutralisation assay, baseline response rates were 86% for XBB.1.5pp, 78% for JN.1pp, 73% for and KP.2pp, 65% for KP.2.3pp and KP.3pp, and 68% for LB.1pp. After vaccination, the response rates for all pseudoviruses increased significantly, and we observed a mean increase in neutralisation of XBB.1.5pp, JN.1pp, KP.2pp, KP.2.3pp, KP.3pp, and LB.1pp of 8.3-fold, 18.7-fold, 22.5-fold, 18.7-fold, 25.5-fold, and 23.5-fold, respectively. In summary, our report provides first evidence for a firm humoral immune response in dialysis patients after mRNA omicron JN.1 vaccination. Our data suggest that the vaccine could be highly effective at enhancing protection of vulnerable populations against evolving SARS-CoV-2 variants.

show abstract

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion

Cited by 7 publications

References 25 publications

A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19

A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants

Humoral Immune Responses in German Dialysis Patients after mRNA Omicron JN.1 Vaccination

Contact Info

Product

Resources

About